Australia has one of the highest rates of methamphetamine dependence in the world. While counselling is effective for many people with less severe dependence, there is no proven medication treatment for severe dependence.
Lisdexamfetamine is a stimulant of the brain and is approved in Australia for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). It is a once-daily oral medication converted to dexamphetamine in the blood.
The aim of The LiMA Study is to test if lisdexamfetamine is effective in reducing methamphetamine use, cravings and withdrawal symptoms.
This will be a randomised double-blind placebo-controlled study which means that one group will receive lisdexamfetamine and another will receive a placebo (a medication with no active ingredients), in addition to counselling. Participants, clinicians and researchers involved in the study will not know to which group they have been allocated. The two groups will be compared and the findings will contribute to evidence for the future use of lisdexamfetamine in the treatment of methamphetamine dependence.
180 people will be recruited to The LiMA Study which will be conducted in specialist treatment centres in Sydney, Newcastle, Adelaide and Melbourne. Recruitment is now open.